Abstract
Increased urokinase receptor (uPAR) expression as well as stabilisation of uPAR mRNA contribute to the pathogenesis of lung inflammation and neoplasia. Post-transcriptional regulation of uPAR mRNA involves interaction of both coding and 3′-UTR sequences with regulatory uPAR mRNA binding proteins (Bps). In order to identify novel regulatory interactions, we performed gel mobility shift and UV cross-linking assays and found two distinct uPAR mRNA-protein complexes. We identified a rapidly migrating 40 kDa uPAR mRNABp that selectively bound a 110 nucleotide (nt) fragment of the uPAR mRNA 3′UTR. Chimeric β-globin/uPAR mRNA containing the 110 nt 40 kDa protein binding fragment destabilised stable β-globin mRNA with a rate of decay identical to that of chimeric β-globin/uPAR containing the full uPAR 3′UTR. The 40 kDa uPAR 3′UTR Bp was purified using poly (U) sepharose and identified as heterogeneous nuclear ribonucleoprotein C (hnRNPC). Finally, we confirmed its interaction with the uPAR mRNA 3′ UTR by gel mobility supershift assay using an anti-hnRNPC antibody. Direct in vivo interaction of hnRNPC with the uPAR mRNA 3′UTR was demonstrated by immunoprecipitation and combined RT PCR-Southern blotting assay. Co-transfection of hnRNPC cDNA in Beas2B cells reversed destabilisation of chimeric β-globin/uPAR 3′UTR mRNA and its over-expression also induced uPAR protein and mRNA expression through stabilisation of uPAR mRNA. These observations indicate a novel mechanism of uPAR gene regulation in lung epithelial cells in which cis elements within a 110 nt uPAR mRNA 3′UTR sequence interact with hnRNPC to regulate uPAR mRNA stability.
Similar content being viewed by others
References
Mazar AP, Henkin J, Goldfarb RH: The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15–32, 1999
Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Engl J Med 315: 1650–1659, 1986
Dvorak HF, Senger DR, Dvorak AM: Fibrin as a component of the tumor stroma: Origins and biological significance. Cancer Met Rev ([0-9]+): 41–73, 1983
Vassalli JD, Sappino AP, Belin D: The plasminogen activator/plasmin system. J Clin Invest 88: 1067–1072, 1991
Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen, LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139–266, 1985
Liotta LA, Stetler-Stevenson WG, Steeg PS: Cancer invasion and metastasis: Positive and negative regulatory elements. Cancer Invest 9: 543–551, 1991
Mignatti P, Rifkin, DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161–195, 1993
Idell S: Extravascular coagulation and fibrin deposition in acute lung injury. New Horizons 2: 566–574, 1994
Idell S: Coagulation, fibrinolysis and fibrin deposition in lung injury and repair. In: S.H. Phan, R.S. Thrall (eds.) Pulmonary Fibrosis. Lung Biology in Health and Disease. Vol. 80, Marcel Dekker, New York, 1995, pp. 743–776
Chapman HA, Bertozzi P, Reilly, JJ: Role of enzymes mediating thrombosis and thrombolysis in lung disease. Chest 93: 1256–1263, 1988
Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671–4675, 1994
Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K, Brunner N: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120–123, 1994
Blasi F, Vassalli JD, Dano K: Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors. J Cell Biol 104: 801–804, 1987
Lund LR, Ellis V, Ronne E, Pyke C, Dano K: Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549. Biochem J 310: 345–352, 1995
Lund LR, Ronne E, Roldan AL, Behrendt N, Romer J, Blasi F, Dano, K: Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J Biol Chem 266: 5177–5181, 1991
Shetty S, Kumar A, Idell S: Posttranscriptional regulation of urokinase receptor mRNA: Identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol 17: 1075–1083, 1997
Wang Y., Jones CJ, Dang J, Liang X, Olsen, JE, Doe, WF: Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett 353: 138–142, 1994
Wang GJ, Collinge M, Blasi F, Pardi R, Bender JR: Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. Proc Natl Acad Sci 95: 6296–6301, 1998
Shetty S, Idell, S: Post-transcriptional regulation of urokinase mRNA. Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro. J Biol Chem 275: 13771–13779, 2000
Shetty S, Idell S: Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro. Am J Physiol 278: L148–156, 2000
Shetty S, Idell S: Pottranscriptional regulation of urokinase receptor gene expression in lung carcinoma and malignant mesothelioma cells in vitro. Mol Cell Biochem 199: 189–200, 1999
Shetty S, Idell S: A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Arch Biochem Biophys 356: 265–279, 1998
Shetty S, Idell S: A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells. Am J Physiol 274: L871–L882, 1998
Heaton JH, Tillman-Bogush M, Leff NS, Gelehrter TD: Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. J Biol Chem 273: 14261–14268, 1998
Tillman-Bogush M, Heaton, JH, Gelehrter, TD: Cyclic nucleotide regulation of PAI-1 mRNA stability: Dentification of cytosolic proteins that interact with an A-Rich sequence. J Biol Chem 274: 1172–1179, 1999
Heaton JH, Dlakic WM, Dlakic M, Gelehrter TD: Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-response sequence in the type-1 plasminogen activator inhibitor mRNA. J Biol Chem 273: 14261–14268, 2001
Maurer F, Tiernay M, Medcalf RL: An AU-rich sequence in the 3′-UTR of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuR. Nucl Acid Res 27: 1664–1673, 1999
Tiernay M, Medcalf RL: Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. J Biol Chem 276: 13675–13684, 2001
Pepper MS, Matsumoto K, Nakamura T, Orci L, Montesano R: Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 267: 20493–20496, 1992
Shetty S, Kumar A, Johnson A, Idell S: Regulation of mesothelial cell mitogenesis by antisense oligonucleotides for the urokinase receptor. Antisense Res Dev 5: 307–314: 1995
Shetty S, Kumar A, Johnson A, Pueblitz S, Idell S: Urokinase receptor in human malignant mesothelioma cells: Role in tumor cell mitogenesis and proteolysis. Am J Physiol 268: L972–L982, 1995
Shetty S, Idell S: Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J Biol Chem 276: 24549–24556, 2001
Shetty S, Penduthiri U, Halady PKS, Azghani A, Idell S: Urokinase induces its own expression in Beas2B lung epithelial cells. Am J Physiol 283: L319–l328, 2002
Shetty S, Khalil B, Cines DB, Idell S: Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem 278: 18124–18131, 2003
Waltz DA, Sailor LZ, Chapman HA: Cytokines induce urokinase-dependent adhesion of human myeloid cells. J Clin Invest ([0-9]+): 1541–1552, 1993
Bhat GJ, Gunaje JJ, Idell S: Urokinase-type plasminogen activator induces tyrosine phosphorylation of a 78-kDa protein in H-157 cells. Am J Physiol 277: L301–L309, 1999
Montuori N, Mattiello A, Mancini A, Santoli M, Taglialatela P, Caputi M, Rossi G, Ragno P: Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor through a posttranscriptional mechanism. FEBS Lett 508: 379–384, 2001
Shetty S, Idell S: Urokinase receptor mRNA stability Involves Tyrosine phosphorylation in lung epithelial cells. Am J Resp Cell Mol Biol 30: 69–75, 2003
Xing RH, Mazar A, Henkin J, Rabbani SA: Prevention of breast cancer growth, invasion, and metastasis by anti-estrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res ([0-9]+): 3585–3593, 1997
Achbarou A, Kaiser S, Tremblay G, Ste-Marie L, Brodt GP, Goltzman, D, Rabbani. SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res ([0-9]+): 2372–2377, 1994
Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F, Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thromb Haemost 78: 285–296, 1997
Hollas W, Hoosein N, Chung LW, Mazar A, Henkin J, Kariko K, Barnathan E, Boyd D: Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost 68: 662–666, 1992
Mitsubayashi S, Akiyama T, Kurita T, Okada K, Bando H, Sakai T, Matsuo O: Plasminogen activator in bladder tumors. Urol Res 15: 335–339, 1987
Boyd D, Florent G, Kim P, Brattain M: Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48: 3112–3116, 1988
Rajagopalan LE, Westmark CJ, Jarzembowski JA, Malter JS: hnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA. Nucleic Acid Res 26: 3418–3423, 1998
Nanbu R, Nagamine Y: Enhanced stability of urokinase-type plasminogen activator mRNA in metastatic breast cancer MDA_MB-231 cells and LLC-PK1 cells down-regulated for protein kinase C. Eur J Biochem 247: 169–174, 1997
Nanbu R, Menoud, PA, Nagamine Y: Multiple instability-regulating sites in the 3′untranslated region of the urokinase – type plasminogen activator mRNA. Mol Cell Biol 14: 4920–4928, 1994
Burd CG, Dreyfuss G: Conserved structures and diversity of functions of RNA-binding proteins. Science 265: 615–621, 1994
Shyu AB, Wilkinson MF: The double lives of shuttling mRNA binding proteins. Cell 102: 135–138, 2000
Shetty S: Protein synthesis and urokinase mRNA metabolism Mol. Cell. Biochem. (in press).
Tran H, Maurer F, Nagamine Y: Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated kinase 2. Mol Cell Biol 23: 7177–7188, 2003
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shetty, S. Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells. Mol Cell Biochem 272, 107–118 (2005). https://doi.org/10.1007/s11010-005-7644-2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11010-005-7644-2